Addyi and Bupropion Interaction: Safety, Mechanism, and Clinical Guidance

Why This Interaction Matters

Flibanserin and bupropion are prescribed together more often than most clinicians realize, because the two drugs treat conditions that frequently overlap. Flibanserin (brand name Addyi) is the only FDA-approved oral treatment for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women [1]. Bupropion, an aminoketone-class norepinephrine-dopamine reuptake inhibitor (NDRI), treats major depressive disorder and is one of the few antidepressants associated with neutral or even positive effects on sexual function [2]. Women taking an SSRI or SNRI who develop sexual side effects are often switched to bupropion. If that same patient also carries an HSDD diagnosis, both drugs may land on the medication list simultaneously.

The interaction sits at a moderate severity tier, not at the "hard contraindication" level occupied by strong CYP3A4 inhibitors such as ketoconazole or fluconazole, which are explicitly contraindicated with flibanserin per the FDA-approved Addyi label [1]. That distinction is important. A moderate interaction demands vigilance, not avoidance.

The Pharmacokinetic Mechanism: CYP2D6 Inhibition

Flibanserin undergoes extensive hepatic metabolism. The two primary enzymes responsible are CYP3A4, which accounts for the largest share of clearance, and CYP2D6, which serves as a secondary but clinically meaningful pathway [1]. Bupropion and its active metabolite hydroxybupropion are well-characterized moderate inhibitors of CYP2D6 [3]. When bupropion blocks this secondary clearance route, less flibanserin is metabolized per unit time, and systemic exposure rises.

The FDA's clinical pharmacology review for Addyi quantified the effect of moderate CYP2D6 inhibitors on flibanserin exposure. Co-administration produced a roughly 21% increase in flibanserin area under the curve (AUC) [1]. For context, strong CYP3A4 inhibitors raise flibanserin AUC by 4.5-fold. The difference between a 21% bump and a 350% spike explains why bupropion is flagged but not contraindicated.

A second layer of pharmacodynamic overlap also exists. Both drugs affect central monoamine signaling. Flibanserin acts as a 5-HT1A agonist and 5-HT2A antagonist while also modestly increasing dopamine and norepinephrine in certain brain regions [4]. Bupropion inhibits reuptake of dopamine and norepinephrine directly [3]. The additive noradrenergic activity may amplify cardiovascular effects (blood-pressure drops, reflex tachycardia), particularly during postural changes.

Quantifying the Risk: What the Clinical Data Show

No dedicated randomized trial has studied the flibanserin-bupropion pair head-to-head. The evidence base rests on three sources: the Addyi NDA pharmacokinetic studies, post-marketing adverse-event data, and extrapolation from the known pharmacology of each drug.

In the key BEGONIA trial (N=1,087) [5], flibanserin 100 mg at bedtime produced statistically significant improvements in satisfying sexual events and desire scores versus placebo over 24 weeks. Adverse events in the flibanserin arm included dizziness (11.4%), somnolence (11.2%), nausea (10.4%), and fatigue (5.2%). The BEGONIA population excluded women on moderate or strong CYP2D6 inhibitors, so the trial data do not directly capture the co-administration scenario.

Population pharmacokinetic modeling conducted during FDA review estimated that CYP2D6 poor metabolizers (PMs), who effectively have zero CYP2D6 activity, experienced flibanserin AUC values approximately 35% higher than extensive metabolizers [1]. Bupropion co-administration mimics a partial PM phenotype, producing exposures somewhere between the 21% (moderate inhibition) and 35% (complete absence of CYP2D6) thresholds. The clinical significance is a modest but real increase in the rates of dizziness, somnolence, and orthostatic hypotension.

Post-marketing pharmacovigilance data from the FDA Adverse Event Reporting System (FAERS) [6] include reports of syncope in women taking flibanserin with CYP2D6 inhibitors, though the absolute numbers remain low given the small commercial patient base. The FAERS data cannot establish causation, but they align with the predicted pharmacokinetic interaction.

The Alcohol Variable: A Non-Negotiable Restriction

Any discussion of flibanserin drug interactions must address alcohol, because it transforms a moderate interaction into a dangerous one. The Addyi REMS program exists primarily because of the flibanserin-alcohol interaction [7]. In a dedicated interaction study, concurrent use of flibanserin 100 mg and 0.4 g/kg ethanol caused severe hypotension (systolic blood pressure <70 mmHg in some subjects) and syncope requiring medical intervention [1].

Adding bupropion to a patient who is already taking flibanserin makes strict alcohol avoidance even more critical. The CYP2D6 inhibition from bupropion raises baseline flibanserin levels, which means the margin of safety against alcohol-induced hypotension shrinks. A patient who "got away with" a single glass of wine on flibanserin alone may not tolerate the same exposure once bupropion is added. The prescribing team should reaffirm the alcohol restriction at every touchpoint.

Dose Adjustment and Prescribing Strategy

The Addyi label does not mandate a specific dose reduction for co-administration with moderate CYP2D6 inhibitors [1]. This reflects two realities: flibanserin only comes in a single 100 mg tablet, and the 21% AUC increase was not judged large enough to trigger a mandatory reduction. Compare this to the label's explicit contraindication of strong CYP3A4 inhibitors, where the AUC increase is 4.5-fold.

Practical prescribing guidance falls into a few categories:

Starting flibanserin in a patient already on bupropion. Begin flibanserin at the standard 100 mg bedtime dose. Schedule a blood-pressure check (seated and standing) at 1 week. If the patient tolerates the combination without orthostatic symptoms, continue with routine follow-up.

Adding bupropion in a patient already on flibanserin. Titrate bupropion per its own labeling (typically starting at 150 mg SR daily, advancing to 150 mg SR twice daily). Re-check orthostatic vitals 5 to 7 days after reaching the target bupropion dose.

Patients on both drugs who develop dizziness or presyncope. First, confirm alcohol abstinence. Second, check for other CYP3A4 inhibitors that may have been added (oral contraceptives containing ethinyl estradiol are weak CYP3A4 inhibitors and are common in this population). Third, consider whether the flibanserin can be held temporarily while the symptom is evaluated.

Dr. Sheryl Kingsberg, a clinical psychologist and HSDD researcher at University Hospitals Cleveland Medical Center, has noted: "The therapeutic goal with flibanserin is sustained use over months. Stopping and restarting because of a preventable drug interaction undermines the efficacy signal, which builds gradually" [8]. This underscores the value of anticipating the interaction rather than reacting to it.

CYP3A4 Inhibitors: The Bigger Concern in the Same Patient

Clinicians focused on the bupropion interaction should not lose sight of the far more dangerous category: strong CYP3A4 inhibitors. These are explicitly contraindicated with flibanserin and include ketoconazole, itraconazole, fluconazole, clarithromycin, nefazodone, and certain HIV protease inhibitors [1]. Even moderate CYP3A4 inhibitors (erythromycin, diltiazem, verapamil, grapefruit juice in large quantities) raise flibanserin AUC by roughly 2-fold, requiring a 2-week washout if switching from a strong CYP3A4 inhibitor [1].

Women prescribed both flibanserin and bupropion should receive a full medication reconciliation. If a moderate CYP3A4 inhibitor is also present, the cumulative effect on flibanserin clearance could approach contraindicated territory even though no single interacting drug crosses the threshold alone. The Endocrine Society Clinical Practice Guideline on female sexual dysfunction [9] recommends documenting all CYP3A4 and CYP2D6 interactions before initiating flibanserin.

Monitoring Protocol for Co-Prescribed Patients

A structured monitoring approach reduces the chance of an adverse event progressing to an emergency department visit.

Week 1. Orthostatic blood-pressure measurement (seated x 3 minutes, then standing at 1 and 3 minutes). Ask about dizziness, lightheadedness, and daytime somnolence. Confirm alcohol abstinence.

Week 4. Repeat orthostatic vitals. Assess sexual desire endpoints using a validated instrument such as the Female Sexual Function Index (FSFI) desire domain or the Female Sexual Distress Scale-Revised (FSDS-R) [10]. If no adverse effects have appeared and the patient is tolerating the combination, extend to standard follow-up intervals.

Week 8. Efficacy check. The BEGONIA [5] and VIOLET (N=1,584) [11] trials showed statistically significant separation from placebo by week 8 for both satisfying sexual events and desire scores. If the patient reports no meaningful change in desire by this point, reassess the diagnosis and adherence before assuming treatment failure.

Ongoing. Re-check interactions at every medication change. A new azole antifungal for a vaginal yeast infection, a macrolide antibiotic for a respiratory infection, or a supplement containing goldenseal (a CYP3A4/2D6 inhibitor) can shift the interaction profile rapidly.

Special Populations and Additional Considerations

CYP2D6 poor metabolizers. Approximately 7 to 10% of the Caucasian population and 1 to 2% of Asian and African-American populations are CYP2D6 PMs [12]. In these individuals, bupropion's CYP2D6 inhibition adds nothing further, because the enzyme is already non-functional. Flibanserin levels in PMs are already about 35% higher than in extensive metabolizers [1]. This population does not face additional risk from bupropion co-administration specifically, but they do carry higher baseline flibanserin exposure.

Hepatic impairment. Flibanserin is contraindicated in patients with hepatic impairment of any degree [1]. Bupropion requires dose reduction in moderate-to-severe hepatic impairment [3]. If liver function is borderline, the combination should be avoided entirely.

Concomitant CNS depressants. Diphenhydramine, benzodiazepines, zolpidem, and opioid analgesics all add CNS-depressant load on top of flibanserin's sedating properties. Bupropion itself is not sedating, but by raising flibanserin levels, it amplifies flibanserin's CNS effects indirectly. Review the full medication list for additive sedation.

According to the American Association of Clinical Endocrinology (AACE) 2020 consensus statement on female sexual health, "prescribers should treat HSDD pharmacotherapy with the same interaction vigilance applied to narrow-therapeutic-index drugs, given flibanserin's steep dose-exposure-adverse-event curve" [13].

When the Combination Makes Clinical Sense

Despite the interaction, there are scenarios where prescribing both drugs is the best available option. A premenopausal woman with comorbid major depression and HSDD who has failed SSRIs (which worsen sexual desire) and who responds well to bupropion is a textbook candidate. Removing bupropion to "simplify" the regimen could destabilize her depression. Removing flibanserin sacrifices the only FDA-approved oral therapy for her HSDD.

The decision should be shared. Inform the patient that bupropion modestly raises flibanserin blood levels, that the main risks are dizziness and low blood pressure, that alcohol is absolutely off-limits, and that she should take flibanserin at bedtime (never during the day). With those safeguards in place, the 21% AUC increase is manageable for most patients.

The REMS Dimension

Flibanserin is dispensed only through the Addyi REMS program [14], which requires prescriber certification, pharmacy certification, and patient counseling documentation. The REMS counseling checklist includes a review of concomitant medications, specifically CYP3A4 inhibitors and moderate CYP2D6 inhibitors [1]. Pharmacists filling an Addyi prescription for a patient whose profile also contains bupropion should flag the interaction and document counseling, even though the combination is not a REMS-level contraindication.

The REMS requirement also means that patients cannot casually add flibanserin without prescriber involvement. This built-in safety checkpoint reduces the likelihood of an unmonitored interaction, provided the pharmacy conducts the required drug-utilization review at each fill.

Flibanserin 100 mg at bedtime remains the standard starting and maintenance dose when co-prescribed with bupropion; monitor orthostatic blood pressure at weeks 1, 4, and 8, and reconfirm absolute alcohol avoidance at every visit [1][3].